BR112019024185A2 - Uso de um receptor 2 de peptídeo formila / agonista de receptor a4 lipoxina (fpr2/alx) para tratamento de insuficiência cardíaca - Google Patents
Uso de um receptor 2 de peptídeo formila / agonista de receptor a4 lipoxina (fpr2/alx) para tratamento de insuficiência cardíaca Download PDFInfo
- Publication number
- BR112019024185A2 BR112019024185A2 BR112019024185-0A BR112019024185A BR112019024185A2 BR 112019024185 A2 BR112019024185 A2 BR 112019024185A2 BR 112019024185 A BR112019024185 A BR 112019024185A BR 112019024185 A2 BR112019024185 A2 BR 112019024185A2
- Authority
- BR
- Brazil
- Prior art keywords
- compound
- heart failure
- treatment
- heart
- fact
- Prior art date
Links
- FJZNNKJZHQFMCK-LRDDRELGSA-N COc1cc(F)c([C@H](CNC2=O)[C@@H]2NC(Nc2ccccc2)=O)c(F)c1 Chemical compound COc1cc(F)c([C@H](CNC2=O)[C@@H]2NC(Nc2ccccc2)=O)c(F)c1 FJZNNKJZHQFMCK-LRDDRELGSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/4015—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil having oxo groups directly attached to the heterocyclic ring, e.g. piracetam, ethosuximide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Cardiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Heart & Thoracic Surgery (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Hospice & Palliative Care (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Peptides Or Proteins (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762509489P | 2017-05-22 | 2017-05-22 | |
| US62/509,489 | 2017-05-22 | ||
| PCT/US2018/033783 WO2018217684A1 (en) | 2017-05-22 | 2018-05-22 | Novel use of a formyl peptide receptor 2/ lipoxin a4 receptor (fpr2/alx) agonist for treatment of heart failure |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR112019024185A2 true BR112019024185A2 (pt) | 2020-06-02 |
Family
ID=62567841
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112019024185-0A BR112019024185A2 (pt) | 2017-05-22 | 2018-05-22 | Uso de um receptor 2 de peptídeo formila / agonista de receptor a4 lipoxina (fpr2/alx) para tratamento de insuficiência cardíaca |
Country Status (15)
| Country | Link |
|---|---|
| US (1) | US20200069644A1 (enExample) |
| EP (1) | EP3630097A1 (enExample) |
| JP (1) | JP2020520948A (enExample) |
| KR (1) | KR20200006595A (enExample) |
| CN (1) | CN110662538A (enExample) |
| AU (1) | AU2018273382A1 (enExample) |
| BR (1) | BR112019024185A2 (enExample) |
| CA (1) | CA3064291A1 (enExample) |
| CL (1) | CL2019003325A1 (enExample) |
| CO (1) | CO2019013015A2 (enExample) |
| EA (1) | EA201992704A1 (enExample) |
| IL (1) | IL270749A (enExample) |
| MX (1) | MX2019013926A (enExample) |
| PE (1) | PE20200402A1 (enExample) |
| WO (1) | WO2018217684A1 (enExample) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2869129T3 (es) * | 2017-06-09 | 2021-10-25 | Bristol Myers Squibb Co | Agonistas de piperidinona del receptor 2 de péptidos formilados |
| JP7700210B2 (ja) | 2020-07-09 | 2025-06-30 | ブリストル－マイヤーズ スクイブ カンパニー | ピラゾロンホルミルペプチド２受容体アゴニスト |
| JP7802765B2 (ja) | 2020-08-12 | 2026-01-20 | ブリストル－マイヤーズ スクイブ カンパニー | オキソピロリジン尿素ｆｐｒ２アゴニスト |
| KR20230084530A (ko) * | 2020-10-09 | 2023-06-13 | 브리스톨-마이어스 스큅 컴퍼니 | 아미노이미다졸 fpr2 효능제 |
| CN119055775A (zh) * | 2022-07-30 | 2024-12-03 | 中国医学科学院阜外医院 | Jun抑制剂在制备用于治疗射血分数保留的心衰的药物中的用途 |
| CN118831080B (zh) * | 2024-09-24 | 2024-11-22 | 上海交通大学医学院附属仁济医院 | 5-氧脯氨酸在制备预防或治疗心肌病的药物中的应用 |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1492552A2 (en) * | 2002-04-03 | 2005-01-05 | Bayer Aktiengesellschaft | Diagnostics and therapeutics for diseases associated with n-formyl peptide receptor like 1 (fprl1) |
| NZ752095A (en) | 2013-11-28 | 2022-07-01 | Kyorin Seiyaku Kk | Urea derivative or pharmacologically acceptable salt thereof |
| KR101645015B1 (ko) * | 2014-03-11 | 2016-08-03 | 포항공과대학교 산학협력단 | Fpr2를 활성화하는 물질을 포함하는, 인슐린 저항성 관련 질환 치료용 조성물 |
-
2018
- 2018-05-22 MX MX2019013926A patent/MX2019013926A/es unknown
- 2018-05-22 EP EP18730584.2A patent/EP3630097A1/en not_active Withdrawn
- 2018-05-22 WO PCT/US2018/033783 patent/WO2018217684A1/en not_active Ceased
- 2018-05-22 AU AU2018273382A patent/AU2018273382A1/en not_active Abandoned
- 2018-05-22 JP JP2019564446A patent/JP2020520948A/ja active Pending
- 2018-05-22 CN CN201880033663.XA patent/CN110662538A/zh active Pending
- 2018-05-22 PE PE2019002437A patent/PE20200402A1/es unknown
- 2018-05-22 US US16/612,438 patent/US20200069644A1/en not_active Abandoned
- 2018-05-22 BR BR112019024185-0A patent/BR112019024185A2/pt not_active Application Discontinuation
- 2018-05-22 CA CA3064291A patent/CA3064291A1/en active Pending
- 2018-05-22 KR KR1020197037388A patent/KR20200006595A/ko not_active Withdrawn
- 2018-05-22 EA EA201992704A patent/EA201992704A1/ru unknown
-
2019
- 2019-11-18 IL IL270749A patent/IL270749A/en unknown
- 2019-11-20 CL CL2019003325A patent/CL2019003325A1/es unknown
- 2019-11-21 CO CONC2019/0013015A patent/CO2019013015A2/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| WO2018217684A1 (en) | 2018-11-29 |
| AU2018273382A1 (en) | 2020-01-16 |
| US20200069644A1 (en) | 2020-03-05 |
| CL2019003325A1 (es) | 2020-04-17 |
| PE20200402A1 (es) | 2020-02-26 |
| CN110662538A (zh) | 2020-01-07 |
| IL270749A (en) | 2020-01-30 |
| CO2019013015A2 (es) | 2020-01-17 |
| CA3064291A1 (en) | 2018-11-29 |
| EP3630097A1 (en) | 2020-04-08 |
| EA201992704A1 (ru) | 2020-03-19 |
| MX2019013926A (es) | 2020-01-20 |
| KR20200006595A (ko) | 2020-01-20 |
| JP2020520948A (ja) | 2020-07-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US20200069644A1 (en) | Novel use of a formyl peptide receptor 2/ lipoxin a4 receptor (fpr2/alx) agonist for treatment of heart failure | |
| Koch et al. | Probenecid: novel use as a non-injurious positive inotrope acting via cardiac TRPV2 stimulation | |
| KR102200176B1 (ko) | 신규 방법 | |
| Smith et al. | Nitric oxide precursors and congenital heart surgery: a randomized controlled trial of oral citrulline | |
| TWI305726B (en) | Medicaments for diabetic complication and neuropathy | |
| Yang et al. | Dexmedetomidine attenuates ischemia/reperfusion-induced myocardial inflammation and apoptosis through inhibiting endoplasmic reticulum stress signaling | |
| RU2362555C2 (ru) | Применение замещенных цианопирролидинов и содержащих их комбинированных препаратов для лечения гиперлипидемии и ассоциированных заболеваний | |
| JP2022523645A (ja) | ミトコンドリアミオパチーの処置におけるＰＰＡＲδアゴニストの使用 | |
| BR112013000744A2 (pt) | uso de um antagonista de receptor de tromboxana a2 para prevenção ou tratamento de síndrome hepatorrenal,encefalopatia hepática,e doenças associadas | |
| JP2002128696A (ja) | 肺高血圧の治療 | |
| Zhang et al. | Effect of typhaneoside on ventricular remodeling and regulation of PI3K/Akt/mTOR pathway | |
| JP2016535787A (ja) | 新規方法 | |
| Shi et al. | The histone deacetylase inhibitor SAHA exerts a protective effect against myocardial ischemia/reperfusion injury by inhibiting sodium-calcium exchanger | |
| WO2014028042A1 (en) | Probenecid for treating cardiomyopathy, systolic cardiac dysfunction and the symptoms of congestive heart failure | |
| AU2005238389B2 (en) | Muscle relaxation accelerator and therapeutic agent for muscular tissue diseases such as muscle relaxation failure | |
| CN102076337A (zh) | 决奈达隆的单独或组合在制备用于治疗具有心律失常并具有肌酸酐水平升高的患者的药物中的用途 | |
| JP7569492B2 (ja) | 抗精神病薬誘発性体重増加のミリコリラントによる治療方法 | |
| Leven et al. | Full-dose rivaroxaban in patients with a history of bariatric surgery: bridging the knowledge gap through a phase 1 study | |
| Park et al. | Pheochromocytoma presenting with myocardial infarction, cardiomyopathy, renal failure, pulmonary hemorrhage, and cyclic hypotension: case report and review of unusual presentations of pheochromocytoma | |
| Zhu et al. | [Retracted] Metoprolol Mitigates Ischemic Heart Remodeling and Fibrosis by Increasing the Expression of AKAP5 in Ischemic Heart | |
| CN117257803A (zh) | 鲁拉西酮在制备治疗或预防缺血/再灌注损伤的药物和细胞保护药物中的应用 | |
| US12419863B2 (en) | Pharmaceutical composition for use in treatment of hypertrophic cardiomyopathy | |
| BR112019026120A2 (pt) | métodos para reduzir ou prevenir eventos cardio-vasculares em pacientes com diabetes mellitus tipo ii | |
| Raksakietisak et al. | The changes in cortisol levels during cardiac surgery: a randomized double-blinded study between two induction agents etomidate and thiopentone | |
| JP2005531492A (ja) | 高リスク患者のｉｉ型糖尿病を低減させる方法 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B350 | Update of information on the portal [chapter 15.35 patent gazette] | ||
| B06W | Patent application suspended after preliminary examination (for patents with searches from other patent authorities) chapter 6.23 patent gazette] | ||
| B11B | Dismissal acc. art. 36, par 1 of ipl - no reply within 90 days to fullfil the necessary requirements |